|
Status |
Public on May 25, 2017 |
Title |
bladder_cancer_turbt_sample_164 |
Sample type |
RNA |
|
|
Source name |
FFPE bladder cancer
|
Organism |
Homo sapiens |
Characteristics |
disease state: muscle-invasive bladder cancer (MIBC) treatment: pre-NAC sample_type: transurethral resection of bladder tumor (TURBT) age: 58 cstage: T2 cnode: 0 bca_subtype: Basal
|
Treatment protocol |
Not Applicable.
|
Growth protocol |
Not Applicable.
|
Extracted molecule |
total RNA |
Extraction protocol |
After pathologic review, tissue was harvested from formalin-fixed, paraffin-embedded tumor blocks by 1mm punch under RNase-free conditions. Total RNA was extracted and purified using RNeasy FFPE kit (Qiagen, Valencia, CA).
|
Label |
biotin
|
Label protocol |
RNA was amplified, fragmented and biotinylated using the WT-Ovation FFPE system (NuGen, San Carlos, CA) according to the manufacturer’s recommendations with minor modifications.
|
|
|
Hybridization protocol |
Samples were hybridized using Affymetrix hybridization kit materials and protocols.
|
Scan protocol |
Affymetrix GeneChip Scanner 3000 7G.
|
Description |
GNDX.NAC164 bca_subtype=bladder cancer subtype
|
Data processing |
Data was normalized using SCAN (SCAN.UPC package from Bioconductor).
|
|
|
Submission date |
Jan 26, 2017 |
Last update date |
Feb 10, 2019 |
Contact name |
Elai Davicioni |
E-mail(s) |
[email protected]
|
Organization name |
GenomeDx
|
Street address |
1152 Mainland St #430
|
City |
Vancouver |
State/province |
BC |
ZIP/Postal code |
V6B 4X2 |
Country |
Canada |
|
|
Platform ID |
GPL22995 |
Series (1) |
GSE87304 |
Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival outcome to neoadjuvant chemotherapy: results from a multi-institutional validation study |
|